Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection

Hepatology Research

Volumn 46, Issue 3, 2016, Pages E130-E135

  Caviglia, Gian Paolo ^a   Abate, Maria Lorena ^a   Petrini, Elisa ^b   Gaia, Silvia ^b   Rizzetto, Mario ^a,b   Smedile, Antonina ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

Alpha fetoprotein; Des gamma carboxyprothrombin; Hepatocellular carcinoma; Lens culinaris agglutinin reactive fraction of fetoprotein; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; LENS CULINARIS AGGLUTININREACTIVE FRACTION OF ALPHA FETOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOASSAY; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; ITALIAN (CITIZEN); LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84935493188     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12544     Document Type: Article

References (22)

1. Parkin DM, Bray F, Ferlay J etal. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Ioannou GN, Splan MF, Weiss NS etal. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-45.
3. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
4. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
5. Arii S, Sata M, Sakamoto M etal. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667-85.
6. Kokudo N, Hasegawa K, Akahane M etal. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res 2015; 45: 123-7.
7. Johnson PJ, Pirrie SJ, Cox TF etal. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers 2014; 23: 144-53.
8. Toyoda H, Kumada T, Tada T. Highly sensitive Lens culinaris agglutinin-reactive α-fetoprotein: a new tool for the management of hepatocellular carcinoma. Oncology 2011; 81: S61-5.
9. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.
10. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
11. Caviglia GP, Touscoz GA, Smedile A etal. Noninvasive assessment of liver fibrosis: key messages for clinicians. Pol Arch Med Wewne}trznej 2014; 124: 329-35.
12. Kagebayashi C, Yamaguchi I, Akinaga A etal. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Ann Biochem 2009; 388: 306-11.
13. Kobayashi M, Hosaka T, Ikeda K etal. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 2011; 41: 1036-45.
14. Omata M, Lesmana LA, Tateishi R etal. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-74.
15. Singal A, Volk ML, Waljee A etal. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47.
16. Lok AS, Sterling RK, Everhart JE etal. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
17. Rich N, Singal AG. Hepatocellular carcinoma tumour markers: Current role and expectations. Best Pract Res Clin Gastroenterol 2014; 28: 843-53.
18. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39: 1076-84.
19. Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 2001; 20: 99-104.
20. Arguedas MR, Chen VK, Eloubeidi MA etal. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98: 679-90.
21. Sangiovanni A, Del Ninno E, Fasani P etal. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-14.
22. Lok AS, Seeff LB, Morgan TR etal. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-48.